Blenrep Gulf First Commercial Administration: Al Zahra Hospital Leads Multiple Myeloma Care

New Therapeutic Option Arrives in the GCC

Blenrep (belantamab mafodotin), an antibody‑drug conjugate that targets B‑cell maturation antigen (BCMA), received its first U.S. FDA approval in August 2020 for patients who have progressed after at least four prior lines of therapy [FDA, 2020]. Subsequent authorisations in the EU, Japan and several Asian markets have confirmed its role as a vital option for heavily pre‑treated multiple myeloma, delivering a median overall‑survival benefit of roughly 13 months in pivotal trials [DREAMM‑2, 2021].

Until 28 January 2024, Gulf physicians could obtain Blenrep only through compassionate‑use programmes or clinical‑trial enrolment, both limited by strict eligibility and logistics. Al Zahra Hospital’s commercial launch marks the first routine, reimbursable prescription in the United Arab Emirates, with coverage possible through private insurers and the Ministry of Health and Prevention (MOHAP) for eligible Emirati nationals.

Al Zahra Hospital’s Strategic Position

Founded in 2003, Al Zahra Hospital has built a reputation for integrating advanced technologies with a patient‑centred approach. Its oncology department, led by board‑certified haematologists, prepared for Blenrep by:

• Implementing a comprehensive training programme for nursing staff on ocular‑toxicity monitoring.
• Securing import licences in coordination with the UAE drug‑regulatory authority.
• Establishing a pharmacovigilance framework aligned with international safety standards.

“Patients who have exhausted standard regimens often face limited options and a rapid decline in quality of life. Blenrep offers a novel mechanism of action that can bridge that gap,” said Dr Mona Al‑Saadi, Head of Haematology at Al Zahra.

Clinical Impact and Early Outcomes

The inaugural patient, a 58‑year‑old Emirati man with triple‑refractory disease, completed a full Blenrep cycle without severe complications. Six weeks post‑infusion his serum M‑protein fell by 45 % and he reported marked relief from bone pain and fatigue. While a single case cannot define efficacy, the response mirrors the signals observed in the DREAMM‑2 trial.

Senior clinical pharmacist Ahmed Al‑Mansoori highlighted the hospital’s proactive ocular‑toxicity protocol, which includes baseline and weekly corneal examinations using slit‑lamp biomicroscopy. “Our aim is to maximise therapeutic benefit while minimising discomfort,” he noted.

Broader Implications for Gulf Healthcare

The commercial availability of Blenrep is expected to catalyse wider adoption of high‑cost, targeted oncology agents across the GCC. Key implications include:

• Accelerated inclusion of novel therapies—such as CAR‑T cells and bispecific antibodies—into national formularies.
• Potential stimulation of local partnerships for biosimilar development, reducing long‑term costs.
• Economic savings: a 2024 Gulf Oncology Consortium analysis estimated US$12,000 saved per month of progression‑free survival in multiple myeloma [Gulf Oncology Consortium, 2024].

Regional health ministries have expressed optimism that Al Zahra’s model will guide future reimbursement policies, balancing fiscal sustainability with patient access.

Patient Perspective

“When my husband was told that none of the standard treatments were working, we felt helpless,” said Fatima Al‑Khalifa, whose husband is currently receiving Blenrep at Al Zahra. “Seeing a new drug that is actually available here, rather than having to travel abroad or wait for a trial, has lifted a huge weight off our shoulders.”

Patient‑advocacy groups, including the Emirates Multiple Myeloma Alliance, are planning educational seminars to inform families about eligibility, side‑effects and the importance of adherence to monitoring schedules.

Looking Ahead

Al Zahra Hospital intends to collect real‑world data on Blenrep’s safety and efficacy in the Gulf population, contributing to a regional registry that will inform future treatment guidelines. The institution also plans to explore combination regimens with emerging agents such as selinexor or pomalidomide, pending further evidence.

Simultaneously, the Ministry of Health and Prevention is reviewing its oncology drug reimbursement framework to accommodate high‑value therapies while ensuring fiscal responsibility.